I was able to hop back on the call to ask a couple
Post# of 36537
(Total Views: 348)
Posted On: 01/21/2020 11:21:01 AM
I was able to hop back on the call to ask a couple of those Qs:
Joe is not concerned with liquidity over the next couple of months as we try to close the S-1 funding. As we wait for the 10-Q in mid-Feb, we can choose individually what level of confidence we have in that. Joe seemed dismissive of the idea that we would have ST liquidity issues, as he has options to come up with operating cash. I felt confident in his response.
- Excellagen $450k revs in November. I would think this would only go up from here, as more approvals are granted and product usage proves out the efficacy to more doctors/clinics. Money stays w Excellagen, so I would think this would only help accelerate sales (in an emergency, I would think Joe could tap these funds short-term, as accommodating as the Olaregen bunch has been to-date w extensions on payments, etc.).
- There is one Asian licensing deal for Excellagen that seems like it might be close to closing.
- Pantheon/Medisource had "significant" increases in sales in the last Q.
Overall, I am going to choose to be patient on (and maybe even try to ignore until significant news comes out) all the funding/div/illegal sales crap at this point. Joe is confident in keeping the ship afloat until these items resolve, so I feel a little better than before the call. The assets are there, and if/when we get to the S-1/NGIO spin, we will be off to the races.
Had to drop back off... please post any significant items you hear...
Joe is not concerned with liquidity over the next couple of months as we try to close the S-1 funding. As we wait for the 10-Q in mid-Feb, we can choose individually what level of confidence we have in that. Joe seemed dismissive of the idea that we would have ST liquidity issues, as he has options to come up with operating cash. I felt confident in his response.
- Excellagen $450k revs in November. I would think this would only go up from here, as more approvals are granted and product usage proves out the efficacy to more doctors/clinics. Money stays w Excellagen, so I would think this would only help accelerate sales (in an emergency, I would think Joe could tap these funds short-term, as accommodating as the Olaregen bunch has been to-date w extensions on payments, etc.).
- There is one Asian licensing deal for Excellagen that seems like it might be close to closing.
- Pantheon/Medisource had "significant" increases in sales in the last Q.
Overall, I am going to choose to be patient on (and maybe even try to ignore until significant news comes out) all the funding/div/illegal sales crap at this point. Joe is confident in keeping the ship afloat until these items resolve, so I feel a little better than before the call. The assets are there, and if/when we get to the S-1/NGIO spin, we will be off to the races.
Had to drop back off... please post any significant items you hear...
(1)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼